{"success":true,"data":{"pressRelease":{"id":"38138","rtpr_id":"nBw74HslWa","ticker":"ALMKT","exchange":"Euronext Paris","all_tickers":["ALMKT"],"title":"Mauna Kea Technologies Announces Nomination of 3 New Directors","author":"Business Wire","published_at":"2026-05-18T15:45:00.138Z","article_body":"Mauna Kea Technologies Announces Nomination of 3 New Directors\n\nTheir recognized expertise will help accelerate the strategic transformation\nlaunched in 2025\n\nSubject to approval at upcoming Annual General Meeting\n\nRegulatory News:\n\nMauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio(®),\nthe multidisciplinary probe and needle-based confocal laser endomicroscopy\n(p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli\nHofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of\nDirectors will be submitted for shareholder approval at the Annual General\nMeeting to be held on June 4, 2026. Internet voting opened today (details\nbelow).\n\nIf approved by shareholders, Mr. Richard Di Benedetto will replace Ms. Claire\nBiot, and Mr. Randall Stanicky will replace Ms. Jacquelien Ten Dam, as their\nrespective terms come to an end. Ms. Elsy Boglioli Hofman is proposed as a\nnewly appointed member of the Board. Richard Di Benedetto, Randall Stanicky\nand Elsy Boglioli Hofman would join Molly O’Neill, Christopher McFadden and\nSacha Loiseau, whose terms are proposed to be renewed.\n\nThe addition of these three international leaders reflects the profound\ntransformation that Mauna Kea Technologies has undergone over the past year.\nTheir combined expertise in operational management, global growth strategies,\nand North American capital markets will strongly support the Company’s\ncommercial and market development ambitions.\n\nSacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented:\n“We are gratified that these accomplished leaders have agreed to join the\nMauna Kea Technologies Board of Directors. I believe they can make a\nsignificant contribution toward enabling Cellvizio to reach its full\ncommercial potential. As such, I urge shareholders to approve these\nnominations at or before our June 4 AGM. As importantly, I would like to thank\nClaire Biot and Jacquelien Ten Dam whose contribution of time, insights, and\nwisdom helped make Mauna Kea a better organization.”\n\nProfiles of the Proposed Board Members:\n\nElsy Boglioli Hofman – Strategic Advisor and Senior Life Sciences Executive\n\nA recognized expert in the healthcare and biotechnology sectors, Elsy Boglioli\nHofman has led Bio-Up, a strategic advisory firm for HealthTech leaders, since\n2019. Her professional background includes high-level executive roles, notably\nas Chief Operating Officer of Cellectis and Partner & Managing Director at\nthe Boston Consulting Group (BCG). An experienced board member, she currently\nserves as an Independent Director for FTI Consulting (NYSE) and GenSight\nBiologics (Euronext) and chairs the Board of TreeFrog Therapeutics. She is a\ngraduate of École Polytechnique.\n\nRichard Di Benedetto – Global Medtech Leader\n\nA globally recognized leader in the healthcare sector, Richard Di Benedetto\nbrings extensive executive experience from world-leading organizations. He\ncurrently serves as Chairman of Alliance Medical Group and Chairman of the\nBoard of T2S Group, while also holding a Non-Executive Director position at\nVanguard Healthcare Solutions. His distinguished career is highlighted by his\ndecade-long tenure as President of Aetna International (CVS Health group),\noverseeing global health benefits, and as CEO of Euromedic International. He\nalso spent 15 years at GE Healthcare in various senior roles, including\nPresident and CEO for the Middle East, Africa, and Russia regions. An expert\nin global growth strategies, he holds a Master’s degree in Economics from\nthe Institut d'Études Politiques de Paris. Richard Di Benedetto holds\n1,027,749 shares of Mauna Kea Technologies from the November 2025 capital\nincrease.\n\nRandall Stanicky – U.S. Capital Markets and Corporate Finance Executive\n\nA recognized expert in financing medical innovation, Randall Stanicky brings\nover 20 years of Wall Street experience. He currently serves as Chief\nFinancial Officer of Click Therapeutics, where he has successfully led several\ndebt and equity fundraising rounds. His professional background includes\nhigh-level executive roles with leading global investment banks, with most of\nhis sell-side career spent at Goldman Sachs. An experienced board member, he\ncurrently serves on the boards of Cellphire Therapeutics and Children's Tumor\nFoundation (Honorary), and previously served on the board of TherapeuticsMD.\nHe holds a Bachelor of Commerce from the University of British Columbia (UBC).\n\nInformation Regarding the Annual General Meeting and Voting Procedures\n\nThe Combined General Meeting of Mauna Kea Technologies will be held on June 4,\n2026, at 11:00 a.m. (CEST) at the Company's headquarters (9, rue d'Enghien,\n75010 Paris).\n\nInternet voting will be open via the secure VOTACCESS platform starting from\nMay 18, 2026, at 9:00 a.m. (CEST) until June 3, 2026, at 3:00 p.m. (CEST).\nShareholders may also vote by mail or by proxy (postal votes must be received\nby May 31, 2026, at 11:59 p.m.). All documentation regarding the General\nMeeting, including the detailed convening notice and voting instructions, is\navailable in the Investors section of the Company's\nwebsite:https://www.maunakeatech.com/governance/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.maunakeatech.com%2Fgovernance%2F&esheet=54537624&newsitemid=20260518500637&lan=en-US&anchor=https%3A%2F%2Fwww.maunakeatech.com%2Fgovernance%2F&index=1&md5=48f4cf1332a35749ebd32df775e79ca9)\n.\n\nAbout Mauna Kea Technologies\n\nMauna Kea Technologies is a global medical device company that manufactures\nand sells Cellvizio(®), the real-time in vivo cellular imaging platform. This\ntechnology uniquely delivers in vivo cellular visualization which enables\nphysicians to monitor the progression of disease over time, assess\npoint-in-time reactions as they happen in real time, classify indeterminate\nareas of concern, and guide surgical interventions. The Cellvizio(®) platform\nis used globally across a wide range of medical specialties and is making a\ntransformative change in the way physicians diagnose and treat patients. For\nmore information, visit www.maunakeatech.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.maunakeatech.com&esheet=54537624&newsitemid=20260518500637&lan=en-US&anchor=www.maunakeatech.com&index=2&md5=2bb61153e63b28e562af0fd7754cae66)\n.\n\nDisclaimer\n\nThis press release contains forward-looking statements about Mauna Kea\nTechnologies and its business. All statements other than statements of\nhistorical fact included in this press release, including, but not limited to,\nstatements regarding Mauna Kea Technologies' financial condition, business,\nstrategies, plans and objectives for future operations are forward-looking\nstatements. Mauna Kea Technologies believes that these forward-looking\nstatements are based on reasonable assumptions. However, no assurance can be\ngiven that the expectations expressed in these forward-looking statements will\nbe achieved. These forward-looking statements are subject to numerous risks\nand uncertainties, including those described in Chapter 2 of Mauna Kea\nTechnologies' 2025 Annual Report filed with the Autorité des marchés\nfinanciers (AMF) on April 30, 2026, which is available on the Company's\nwebsite (www.maunakeatech.fr\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.maunakeatech.fr&esheet=54537624&newsitemid=20260518500637&lan=en-US&anchor=www.maunakeatech.fr&index=3&md5=6c25c3457fad930760609bf4f231776b)\n), as well as the risks associated with changes in economic conditions,\nfinancial markets and the markets in which Mauna Kea Technologies operates.\nThe forward-looking statements contained in this press release are also\nsubject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea\nTechnologies does not currently consider material. The occurrence of some or\nall of these risks could cause the actual results, financial condition,\nperformance or achievements of Mauna Kea Technologies to differ materially\nfrom those expressed in the forward-looking statements. This press release and\nthe information contained herein do not constitute an offer to sell or\nsubscribe for, or the solicitation of an order to buy or subscribe for, shares\nof Mauna Kea Technologies in any jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such jurisdiction. The distribution of this\npress release may be restricted in certain jurisdictions by local law. Persons\ninto whose possession this document comes are required to comply with all\nlocal regulations applicable to this document.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260518500637/en/\n(https://www.businesswire.com/news/home/20260518500637/en/)\n\nMauna Kea Technologies \n\ninvestors@maunakeatech.com (mailto:investors@maunakeatech.com)\n\nNewCap - Investor Relations \n\nThomas Grojean\n\n+33 (0)1 44 71 94 94\n\nmaunakea@newcap.eu (mailto:maunakea@newcap.eu)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw74HslWa","title":"Mauna Kea Technologies Announces Nomination of 3 New Directors","author":"Business Wire","ticker":"ALMKT","created":"2026-05-18T15:45:00.138Z","tickers":["ALMKT"],"exchange":"Euronext Paris","article_body":"Mauna Kea Technologies Announces Nomination of 3 New Directors\n\nTheir recognized expertise will help accelerate the strategic transformation\nlaunched in 2025\n\nSubject to approval at upcoming Annual General Meeting\n\nRegulatory News:\n\nMauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio(®),\nthe multidisciplinary probe and needle-based confocal laser endomicroscopy\n(p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli\nHofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of\nDirectors will be submitted for shareholder approval at the Annual General\nMeeting to be held on June 4, 2026. Internet voting opened today (details\nbelow).\n\nIf approved by shareholders, Mr. Richard Di Benedetto will replace Ms. Claire\nBiot, and Mr. Randall Stanicky will replace Ms. Jacquelien Ten Dam, as their\nrespective terms come to an end. Ms. Elsy Boglioli Hofman is proposed as a\nnewly appointed member of the Board. Richard Di Benedetto, Randall Stanicky\nand Elsy Boglioli Hofman would join Molly O’Neill, Christopher McFadden and\nSacha Loiseau, whose terms are proposed to be renewed.\n\nThe addition of these three international leaders reflects the profound\ntransformation that Mauna Kea Technologies has undergone over the past year.\nTheir combined expertise in operational management, global growth strategies,\nand North American capital markets will strongly support the Company’s\ncommercial and market development ambitions.\n\nSacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented:\n“We are gratified that these accomplished leaders have agreed to join the\nMauna Kea Technologies Board of Directors. I believe they can make a\nsignificant contribution toward enabling Cellvizio to reach its full\ncommercial potential. As such, I urge shareholders to approve these\nnominations at or before our June 4 AGM. As importantly, I would like to thank\nClaire Biot and Jacquelien Ten Dam whose contribution of time, insights, and\nwisdom helped make Mauna Kea a better organization.”\n\nProfiles of the Proposed Board Members:\n\nElsy Boglioli Hofman – Strategic Advisor and Senior Life Sciences Executive\n\nA recognized expert in the healthcare and biotechnology sectors, Elsy Boglioli\nHofman has led Bio-Up, a strategic advisory firm for HealthTech leaders, since\n2019. Her professional background includes high-level executive roles, notably\nas Chief Operating Officer of Cellectis and Partner & Managing Director at\nthe Boston Consulting Group (BCG). An experienced board member, she currently\nserves as an Independent Director for FTI Consulting (NYSE) and GenSight\nBiologics (Euronext) and chairs the Board of TreeFrog Therapeutics. She is a\ngraduate of École Polytechnique.\n\nRichard Di Benedetto – Global Medtech Leader\n\nA globally recognized leader in the healthcare sector, Richard Di Benedetto\nbrings extensive executive experience from world-leading organizations. He\ncurrently serves as Chairman of Alliance Medical Group and Chairman of the\nBoard of T2S Group, while also holding a Non-Executive Director position at\nVanguard Healthcare Solutions. His distinguished career is highlighted by his\ndecade-long tenure as President of Aetna International (CVS Health group),\noverseeing global health benefits, and as CEO of Euromedic International. He\nalso spent 15 years at GE Healthcare in various senior roles, including\nPresident and CEO for the Middle East, Africa, and Russia regions. An expert\nin global growth strategies, he holds a Master’s degree in Economics from\nthe Institut d'Études Politiques de Paris. Richard Di Benedetto holds\n1,027,749 shares of Mauna Kea Technologies from the November 2025 capital\nincrease.\n\nRandall Stanicky – U.S. Capital Markets and Corporate Finance Executive\n\nA recognized expert in financing medical innovation, Randall Stanicky brings\nover 20 years of Wall Street experience. He currently serves as Chief\nFinancial Officer of Click Therapeutics, where he has successfully led several\ndebt and equity fundraising rounds. His professional background includes\nhigh-level executive roles with leading global investment banks, with most of\nhis sell-side career spent at Goldman Sachs. An experienced board member, he\ncurrently serves on the boards of Cellphire Therapeutics and Children's Tumor\nFoundation (Honorary), and previously served on the board of TherapeuticsMD.\nHe holds a Bachelor of Commerce from the University of British Columbia (UBC).\n\nInformation Regarding the Annual General Meeting and Voting Procedures\n\nThe Combined General Meeting of Mauna Kea Technologies will be held on June 4,\n2026, at 11:00 a.m. (CEST) at the Company's headquarters (9, rue d'Enghien,\n75010 Paris).\n\nInternet voting will be open via the secure VOTACCESS platform starting from\nMay 18, 2026, at 9:00 a.m. (CEST) until June 3, 2026, at 3:00 p.m. (CEST).\nShareholders may also vote by mail or by proxy (postal votes must be received\nby May 31, 2026, at 11:59 p.m.). All documentation regarding the General\nMeeting, including the detailed convening notice and voting instructions, is\navailable in the Investors section of the Company's\nwebsite:https://www.maunakeatech.com/governance/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.maunakeatech.com%2Fgovernance%2F&esheet=54537624&newsitemid=20260518500637&lan=en-US&anchor=https%3A%2F%2Fwww.maunakeatech.com%2Fgovernance%2F&index=1&md5=48f4cf1332a35749ebd32df775e79ca9)\n.\n\nAbout Mauna Kea Technologies\n\nMauna Kea Technologies is a global medical device company that manufactures\nand sells Cellvizio(®), the real-time in vivo cellular imaging platform. This\ntechnology uniquely delivers in vivo cellular visualization which enables\nphysicians to monitor the progression of disease over time, assess\npoint-in-time reactions as they happen in real time, classify indeterminate\nareas of concern, and guide surgical interventions. The Cellvizio(®) platform\nis used globally across a wide range of medical specialties and is making a\ntransformative change in the way physicians diagnose and treat patients. For\nmore information, visit www.maunakeatech.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.maunakeatech.com&esheet=54537624&newsitemid=20260518500637&lan=en-US&anchor=www.maunakeatech.com&index=2&md5=2bb61153e63b28e562af0fd7754cae66)\n.\n\nDisclaimer\n\nThis press release contains forward-looking statements about Mauna Kea\nTechnologies and its business. All statements other than statements of\nhistorical fact included in this press release, including, but not limited to,\nstatements regarding Mauna Kea Technologies' financial condition, business,\nstrategies, plans and objectives for future operations are forward-looking\nstatements. Mauna Kea Technologies believes that these forward-looking\nstatements are based on reasonable assumptions. However, no assurance can be\ngiven that the expectations expressed in these forward-looking statements will\nbe achieved. These forward-looking statements are subject to numerous risks\nand uncertainties, including those described in Chapter 2 of Mauna Kea\nTechnologies' 2025 Annual Report filed with the Autorité des marchés\nfinanciers (AMF) on April 30, 2026, which is available on the Company's\nwebsite (www.maunakeatech.fr\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.maunakeatech.fr&esheet=54537624&newsitemid=20260518500637&lan=en-US&anchor=www.maunakeatech.fr&index=3&md5=6c25c3457fad930760609bf4f231776b)\n), as well as the risks associated with changes in economic conditions,\nfinancial markets and the markets in which Mauna Kea Technologies operates.\nThe forward-looking statements contained in this press release are also\nsubject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea\nTechnologies does not currently consider material. The occurrence of some or\nall of these risks could cause the actual results, financial condition,\nperformance or achievements of Mauna Kea Technologies to differ materially\nfrom those expressed in the forward-looking statements. This press release and\nthe information contained herein do not constitute an offer to sell or\nsubscribe for, or the solicitation of an order to buy or subscribe for, shares\nof Mauna Kea Technologies in any jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such jurisdiction. The distribution of this\npress release may be restricted in certain jurisdictions by local law. Persons\ninto whose possession this document comes are required to comply with all\nlocal regulations applicable to this document.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260518500637/en/\n(https://www.businesswire.com/news/home/20260518500637/en/)\n\nMauna Kea Technologies \n\ninvestors@maunakeatech.com (mailto:investors@maunakeatech.com)\n\nNewCap - Investor Relations \n\nThomas Grojean\n\n+33 (0)1 44 71 94 94\n\nmaunakea@newcap.eu (mailto:maunakea@newcap.eu)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-18T15:45:00.175266527Z","server_sent_at_ms":1779119100175},"received_at":"2026-05-18T15:45:00.308Z","source_url":"https://www.businesswire.com/news/home/20260518500637/en/"},"analysis":{"id":"27581","press_release_id":"38138","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Mauna Kea Technologies has nominated three new directors—Elsy Boglioli Hofman, Richard Di Benedetto, and Randall Stanicky—for shareholder approval at its June 4, 2026 Annual General Meeting.\n\nThe new appointments replace outgoing directors Claire Biot and Jacquelien Ten Dam, while Elsy Boglioli Hofman joins as a new member. The board cites their expertise in operational management, global growth, and North American capital markets as key to supporting the company’s strategic transformation.\n\nRichard Di Benedetto, a former GE Healthcare and Aetna International executive, holds over 1 million shares of ALMKT from a November 2025 capital increase. Internet voting for the AGM is open until June 3, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Board refresh with medtech and capital markets veterans signals preparation for next growth phase."},"keyFigures":{"customDimensions":{"shares_held_by_di_benedetto":1027749}},"quotedText":"We are gratified that these accomplished leaders have agreed to join the Mauna Kea Technologies Board of Directors. I believe they can make a significant contribution toward enabling Cellvizio to reach its full commercial potential.","namedEntities":{"people":[{"name":"Elsy Boglioli Hofman","role":"Proposed Director"},{"name":"Richard Di Benedetto","role":"Proposed Director"},{"name":"Randall Stanicky","role":"Proposed Director"},{"name":"Sacha Loiseau","role":"Chairman and CEO"},{"name":"Molly O’Neill","role":"Incumbent Director"},{"name":"Christopher McFadden","role":"Incumbent Director"},{"name":"Claire Biot","role":"Outgoing Director"},{"name":"Jacquelien Ten Dam","role":"Outgoing Director"},{"name":"Thomas Grojean","role":"Investor Relations"}],"products":["Cellvizio","p/nCLE"],"companies":[{"name":"Mauna Kea Technologies","ticker":"ALMKT","relationship":"filer"},{"name":"Bio-Up","relationship":"employer of Elsy Boglioli Hofman"},{"name":"Cellectis","relationship":"former employer of Elsy Boglioli Hofman"},{"name":"Boston Consulting Group","relationship":"former employer of Elsy Boglioli Hofman"},{"name":"FTI Consulting","ticker":"FCN","relationship":"board member of Elsy Boglioli Hofman"},{"name":"GenSight Biologics","relationship":"board member of Elsy Boglioli Hofman"},{"name":"TreeFrog Therapeutics","relationship":"board chair of Elsy Boglioli Hofman"},{"name":"Alliance Medical Group","relationship":"employer of Richard Di Benedetto"},{"name":"T2S Group","relationship":"employer of Richard Di Benedetto"},{"name":"Vanguard Healthcare Solutions","relationship":"employer of Richard Di Benedetto"},{"name":"Aetna International","relationship":"former employer of Richard Di Benedetto"},{"name":"CVS Health","relationship":"parent of Aetna International"},{"name":"Euromedic International","relationship":"former employer of Richard Di Benedetto"},{"name":"GE Healthcare","relationship":"former employer of Richard Di Benedetto"},{"name":"Click Therapeutics","relationship":"employer of Randall Stanicky"},{"name":"Goldman Sachs","relationship":"former employer of Randall Stanicky"},{"name":"Cellphire Therapeutics","relationship":"board member of Randall Stanicky"},{"name":"Children's Tumor Foundation","relationship":"board member of Randall Stanicky"},{"name":"TherapeuticsMD","relationship":"former board member of Randall Stanicky"},{"name":"NewCap","relationship":"Investor Relations advisor"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine board composition update with three new directors nominated for shareholder approval. While the new members bring relevant expertise in medtech and capital markets, this is a standard governance event without immediate financial or operational impact."},"tickerRelevance":{"others":[{"ticker":"FCN","relevance":"mentioned"}],"primary":"ALMKT"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine governance","sectorWeight":"moderate","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Mauna Kea Technologies has nominated three new directors—Elsy Boglioli Hofman, Richard Di Benedetto, and Randall Stanicky—for shareholder approval at its June 4, 2026 Annual General Meeting.\n\nThe new appointments replace outgoing directors Claire Biot and Jacquelien Ten Dam, while Elsy Boglioli Hofman joins as a new member. The board cites their expertise in operational management, global growth, and North American capital markets as key to supporting the company’s strategic transformation.\n\nRichard Di Benedetto, a former GE Healthcare and Aetna International executive, holds over 1 million shares of ALMKT from a November 2025 capital increase. Internet voting for the AGM is open until June 3, 2026.","key_figures":{"customDimensions":{"shares_held_by_di_benedetto":1027749}},"named_entities":{"people":[{"name":"Elsy Boglioli Hofman","role":"Proposed Director"},{"name":"Richard Di Benedetto","role":"Proposed Director"},{"name":"Randall Stanicky","role":"Proposed Director"},{"name":"Sacha Loiseau","role":"Chairman and CEO"},{"name":"Molly O’Neill","role":"Incumbent Director"},{"name":"Christopher McFadden","role":"Incumbent Director"},{"name":"Claire Biot","role":"Outgoing Director"},{"name":"Jacquelien Ten Dam","role":"Outgoing Director"},{"name":"Thomas Grojean","role":"Investor Relations"}],"products":["Cellvizio","p/nCLE"],"companies":[{"name":"Mauna Kea Technologies","ticker":"ALMKT","relationship":"filer"},{"name":"Bio-Up","relationship":"employer of Elsy Boglioli Hofman"},{"name":"Cellectis","relationship":"former employer of Elsy Boglioli Hofman"},{"name":"Boston Consulting Group","relationship":"former employer of Elsy Boglioli Hofman"},{"name":"FTI Consulting","ticker":"FCN","relationship":"board member of Elsy Boglioli Hofman"},{"name":"GenSight Biologics","relationship":"board member of Elsy Boglioli Hofman"},{"name":"TreeFrog Therapeutics","relationship":"board chair of Elsy Boglioli Hofman"},{"name":"Alliance Medical Group","relationship":"employer of Richard Di Benedetto"},{"name":"T2S Group","relationship":"employer of Richard Di Benedetto"},{"name":"Vanguard Healthcare Solutions","relationship":"employer of Richard Di Benedetto"},{"name":"Aetna International","relationship":"former employer of Richard Di Benedetto"},{"name":"CVS Health","relationship":"parent of Aetna International"},{"name":"Euromedic International","relationship":"former employer of Richard Di Benedetto"},{"name":"GE Healthcare","relationship":"former employer of Richard Di Benedetto"},{"name":"Click Therapeutics","relationship":"employer of Randall Stanicky"},{"name":"Goldman Sachs","relationship":"former employer of Randall Stanicky"},{"name":"Cellphire Therapeutics","relationship":"board member of Randall Stanicky"},{"name":"Children's Tumor Foundation","relationship":"board member of Randall Stanicky"},{"name":"TherapeuticsMD","relationship":"former board member of Randall Stanicky"},{"name":"NewCap","relationship":"Investor Relations advisor"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-18T15:45:30.227Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine governance","sectorWeight":"moderate","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":29911,"modelName":"george-droid-qwen-72b"}}